Six The phosphodiesterase-5 inhibitor sildenafil is licensed for PAH in FC I–IV within the USA and FC II–III in Europe. Endothelin receptor antagonists (ERAs) such as bosentan, sitaxentan and ambrisentan are oral therapies accredited to be used in PAH. As no oral agent has proven superiority there stays discussion concerning https://tracleer81345.arwebo.com/49072141/top-guidelines-of-bosentan